Uric acid in heart disease: A new C-reactive protein?

Current Opinion in Rheumatology

Volumn 23, Issue 2, 2011, Pages 174-177

  Krishnan, Eswar ^a   Sokolove, Jeremy ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular; hyperuricemia; risk; uric acid

Indexed keywords

ALLANTOIN; ALLOPURINOL; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; URATE OXIDASE; URIC ACID; XANTHINE OXIDASE;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG MEGADOSE; GENETIC VARIABILITY; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; METABOLIC SYNDROME X; MORTALITY; OBESITY; OBSERVATIONAL STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STABLE ANGINA PECTORIS; STROKE; URIC ACID BLOOD LEVEL;

CARDIOVASCULAR DISEASES; HUMANS; HYPERURICEMIA; RISK; URIC ACID;

EID: 79951581078     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283432dd3     Document Type: Article

References (37)

1. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005; 118:816-826.
2. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for athero- clerosis in gout. Rheumatology (Oxford) 2010; 49:1229-1238.
3. Mazzali M, Kanbay M, Segal MS, et al. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 2010; 12:108-117.
4. Kanbay M,Ozkara A, Selcoki Y, etal. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39:1227-1233. (Pubitemid 350193621)
5. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300:924-932.
6. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999; 85:437-445. (Pubitemid 29409620)
7. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104:2407-2411. (Pubitemid 33108372)
8. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105:2619-2624. (Pubitemid 34596038)
9. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 2005; 91:749-753. (Pubitemid 40769216)
10. Hillis GS, Cuthbertson BH, Gibson PH, et al. Uric acid levels and outcome from coronary artery bypass grafting. J Thorac Cardiovasc Surg 2009; 138:200-205.
11. Sisto T, Paajanen H, Metsa-Ketela T, et al. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg 1995; 59:1519-1523.
12. Coghlan JG, Flitter WD, Clutton SM, et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 107:248-256. (Pubitemid 24050525)
13. Norman A, Ang DS, Ogston S, etal. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375:2161-2167.
14. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114:2508-2516. (Pubitemid 44901524)
15. Khatib SY, Farah H, El-Migdadi F. Allopurinol enhances adenine nucleotide levels and improves myocardial function in isolated hypoxic rat heart. Biochemistry (Mosc) 2001; 66:328-333. (Pubitemid 32445803)
16. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131:7-13. (Pubitemid 29310011)
17. Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10:136-143. (Pubitemid 30171270)
18. Aspirin Myocardial Infarction Study Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243:661-669.
19. Elwood PC. British studies of aspirin and myocardial infarction. Am J Med 1983; 74:50-54. (Pubitemid 13100779)
20. MikulsTR, Farrar JT, Bilker WB, etal. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64:267-272. (Pubitemid 40197509)
21. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 1998; 57:509-510. (Pubitemid 28474054)
22. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57:109-115.
23. Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005; 20:1029-1033.
24. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78:147-153. (Pubitemid 27404949)
25. Bots ML, Grobbee DE, Hofman A, Witteman JC. Common carotid intima-media thickness and risk of acute myocardial infarction: the role of lumen diameter. Stroke 2005; 36:762-767.
26. Tavil Y, Kaya MG, Oktar SO, et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis 2008; 197:159-163. (Pubitemid 351273235)
27. Neogi T, Ellison RC, Hunt S, etal. Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. J Rheumatol 2009; 36:378-384.
28. Kawamoto R, Tomita H, Oka Y, et al. Association between uric acid and carotid atherosclerosis in elderly persons. Intern Med 2005; 44:787-793. (Pubitemid 41263821)
29. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rep 2002; 4:270-274.
30. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:483-495.
31. Gotto AM Jr. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007; 99:718-725.
32. Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009; 55:219-228.
33. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
34. Hingorani AD, Shah T, Casas JP, et al. C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem 2009; 55:239-255.
35. Pepys MB. C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol 2008; 4:234-235. (Pubitemid 351589728)
36. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397. (Pubitemid 38419992)
37. Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on A. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54:2129-2138.